- DIAGNOS Inc. (ADK) has signed a three-year Artificial Intelligence partnership with the University of Montreal Hospital Centre
- The company is a leader in the early detection of health problems using AI
- The AI project will focus on the early detection of various retinal diseases
- Early detection will mean a low cost and a non-invasive methodology for patients
- Shares of DIAGNOS are up 6.35 per cent, and trading at C$0.67
DIAGNOS Inc. (ADK) has signed a three-year Artificial Intelligence (AI) partnership with the University of Montreal Hospital Centre (CHUM).
The company bills itself as a leader in the early detection of critical health problems through AI use.
The AI project will focus on the early detection of various retinal diseases.
Algorithms developed by DIAGNOS will be used to analyze changes in retinal microcirculation and their impacts on the prevention of complications of cardiovascular disease.
The agreement also supports the company’s project to screen diabetic retinopathy with automatic detection assisted by AI.
DIAGNOS president André Larente said the company would like to thank the CHUM for its support in demonstrating the company’s technologies.
“We have different projects that will allow us to develop several innovations in AI with the analysis of the retina. These new developments in early detection of diseases will have a low cost and a non-invasive methodology for patients,” Larente.
As soon as sanitary conditions permit, the technological showcase will resume in the endocrinology (diabetes) and ophthalmology clinics of the CHUM, in order to complete its demonstration phase.
CHUM President and CEO Dr. Fabrice Brunet said the hospice centre is pleased to be working with DIAGNOS.
“The evaluation and refinement of DIAGNOS technology using artificial intelligence in the early detection of certain diseases by our ophthalmology, endocrinology and now cardiology teams contribute to improving the quality and safety of the care provided to the population,” Brunet said.
Headquartered in Quebec, DIAGNOS is dedicated to early detection of health problems based on its FLAIRE AI platform.
Shares of DIAGNOS are up 6.35 per cent, and trading at C$0.67 at 3:29pm EST.